Evogene Ltd. - Ordinary Shares (EVGN) earnings
EVGN earnings moved a median of -3.58% by the close. Quarterly and annual EVGN reports and results, each read against the price at its own news timestamp. Back to the EVGN overview →
21 measured EVGN earnings events.
Where these EVGN earnings landedvs 19 measured EVGN earnings reactions
| Middle 50% of EVGN earnings reactions | -6.47% to -0.68% |
|---|---|
| Median reaction (to close) | -3.58% |
| Measured reactions | 19 |
Point-in-time · zero look-ahead
Half of the 19 EVGN earnings events with a measured close landed between -6.47% and -0.68%; 21% closed up.
| Date | Headline | Event | 5-min | To close |
|---|---|---|---|---|
| Evogene Chairman Nir Nimrodi to Join Quarterly Results Call to Address Current Dissident Shareholders Situation | Press release | -2.29% | -7.57% | |
| Evogene Schedules Second Quarter 2026 Financial Results Release | Press release | -1.96% | -4.04% | |
| Evogene Reports First Quarter 2026 Financial Results | Press release | +4.10% | +2.11% | |
| Evogene Schedules First Quarter 2026 Financial Results Release | Press release | +0.00% | -3.58% | |
| Evogene Reports Third Quarter 2025 Financial Results | Press release | +1.68% | -9.24% | |
| Evogene Schedules Third Quarter 2025 Financial Results Release | Press release | +0.00% | -1.70% | |
| Evogene Reports Second Quarter 2025 Financial Results | Press release | -0.73% | — | |
| Evogene Schedules Second Quarter 2025 Financial Results Release | Press release | +0.00% | — | |
| Evogene Reports First Quarter 2025 Financial Results | Press release | -1.55% | -8.14% | |
| Evogene Schedules First Quarter 2025 Financial Results Release | Press release | -2.56% | -3.42% | |
| Evogene Schedules Fourth Quarter 2024 Financial Results Release | Press release | +0.00% | -5.27% | |
| Evogene Reports Third Quarter 2024 Financial Results | Press release | +0.97% | -0.62% | |
| Evogene Schedules Third Quarter 2024 Financial Results Release | Press release | -0.79% | -5.26% | |
| Evogene Reports Second Quarter 2024 Financial Results | Press release | -0.24% | -14.46% | |
| Evogene Schedules Second Quarter 2024 Financial Results Release | Press release | +0.02% | -5.37% | |
| Evogene Reports First Quarter 2024 Financial Results | Press release | -2.47% | -11.10% | |
| Evogene Schedules First Quarter 2024 Financial Results Release | Press release | +0.00% | -0.75% | |
| Evogene Announces Filing of Annual Report on Form 20-F | Press release | +0.81% | +2.99% | |
| Evogene Schedules Fourth Quarter 2023 Financial Results Release & Conference Call for March 7th, 2024 | Press release | +0.39% | +1.91% | |
| Evogene Reports Third Quarter 2023 Financial Results | Press release | -0.50% | -2.71% | |
| Evogene Schedules Third Quarter 2023 Financial Results Release & Conference Call for November 15, 2023 | Press release | -0.73% | +6.97% |
Keep exploring
More EVGN: analyst actions → · SEC filings → · EVGN overview →
Other Healthcare names and their earnings
| Ticker | Events | Median 30-min | % positive |
|---|---|---|---|
| Allied Healthcare Products, Inc. (AHPI) | 215 | 0.00% | 38% |
| Tactile Systems Technology, Inc. (TCMD) | 215 | +0.25% | 62% |
| AMARANTUS BIOSCIENCE HLDG (AMBS) | 212 | 0.00% | 43% |
| Evoke Pharma, Inc. (EVOK) | 212 | 0.00% | 34% |
Same sector, same measurement: percent move vs. the price at the news timestamp, read at 30 minutes. Sample sizes differ, so the medians are comparable but the confidence behind them is not. These are each name’s all-news baseline, not its earnings — that is what the link opens.